neuroP Cancer Research Results

neuroP, neuroprotective: Click to Expand ⟱
Source:
Type:
Neuroprotective refers to the ability of a substance, intervention, or strategy to preserve the structure and function of nerve cells (neurons) against injury or degeneration.
-While cancer and neurodegenerative processes might seem distinct, there is significant overlap in terms of treatment-related neurotoxicity, shared molecular mechanisms, and the potential for therapies that provide neuroprotection during cancer treatment.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
1999- Api,  doxoR,    Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation
- in-vitro, Nor, NRK52E - in-vitro, Nor, MPC5 - in-vitro, BC, 4T1 - in-vivo, NA, NA
neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,
6719- DHCA,    Anticancer potential of dihydrocaffeic acid: a chlorogenic acid metabolite
- in-vitro, BC, MCF7 - in-vitro, Pca, PC3 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116 - in-vitro, Nor, HDFa
*antiOx↑, *cardioP↑, *neuroP↑, selectivity↑, selectivity↓, TumCCA↑, ROS↑, mtDam↑,
7385- IBC,    Fighting cancer by triggering non-canonical mitochondrial permeability transition-driven necrosis through reactive oxygen species induction
- vitro+vivo, Lung, A549 - in-vitro, BC, 4T1
Apoptosis↑, necrosis↑, ROS↑, mtDam↑, Ca+2↑, MPT↑, MMP↓, AntiCan↑, *AntiBio↑, *Inflam↓, *antiOx↓, *neuroP↑, p‑Akt↓, DHODH↓, Diff↑, MAPK↑,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

DHODH↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↑, 1,   ROS↑, 5,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   MMP↓, 2,   MPT↑, 1,   mtDam↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   FDG↓, 1,   GlutMet↓, 1,   PDH↑, 1,   PFK↓, 1,   POLD1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 3,   Bcl-2↓, 1,   CK2↓, 1,   MAPK↑, 1,   necrosis↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↓, 1,   p62↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   Diff↑, 1,   EMT↓, 1,   FOXO4↓, 1,   IGF-1↓, 1,   mTOR↓, 2,   PI3K↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   E-cadherin↑, 1,   Fibronectin↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 1,   Vim?, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   EGR4↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL1β↓, 1,   PD-1↓, 1,   Th1 response↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen∅, 1,   eff↑, 1,   Half-Life↓, 1,   RadioS↑, 1,   selectivity↓, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   EGFR↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 1,   neuroP↑, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 73

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 4,   GSH↑, 1,   Keap1↓, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 2,   ROS∅, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,   other↓, 1,   other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

ChAT↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   memory↑, 1,   neuroP↑, 4,   toxicity↓, 1,  
Total Targets: 26

Scientific Paper Hit Count for: neuroP, neuroprotective
1 Alpha-Lipoic-Acid
1 Apigenin (mainly Parsley)
1 doxorubicin
1 Dihydrocaffeic Acid
1 Isobavachalcone
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:1105  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page